In 2026, Aurobindo Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Aurobindo Pharma has also provided a category-level breakdown for 8 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2026 | 2025 | 2024 | 2023-2019 |
|---|---|---|---|---|
Total Scope 1 | 912,276a | 750,616a | 414,356a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 533,286a | 474,772a | 553,115a | |
Total Scope 3 | 606,351a | 360,221a | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 255.1698a | 204.3885a | 120.3797a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2026, the total operational greenhouse gas (GHG) emissions of Aurobindo Pharma amounted to 1,445,562 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2025, the total operational greenhouse gas (GHG) emissions of Aurobindo Pharma increased by 17.97%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2026, the total Scope 1 emissions of Aurobindo Pharma were 912,276 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Aurobindo Pharma's Scope 1 emissions have increased by 122.74%, reflecting a rising long-term trend in Scope 1 emissions over time.ac
Compared to the previous year (2025), Aurobindo Pharma's Scope 1 emissions increased by 21.54%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2026, Aurobindo Pharma reported Scope 2 greenhouse gas (GHG) emissions of 533,286 tCO₂e without specifying the calculation method.a
Since 2019, Aurobindo Pharma's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Aurobindo Pharma's emissions have plateaued with no significant change in its energy consumption footprint.ac
Compared to the previous year (2025), Aurobindo Pharma's Scope 2 emissions (Unspecified Calculation Method) rose by 12.32% in 2026, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2026, Aurobindo Pharma reported its Scope 2 emissions using an unspecified methodology.a
In 2026, Aurobindo Pharma reported 606,351 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2026 disclosure of Aurobindo Pharma includes a breakdown across 6 of the 15 Scope 3 categories defined by the GHG Protocol, down from 8 in 2025, indicating a decline in reporting granularity and reduced insight into the company's full value chain emissions.a
In 2026, Aurobindo Pharma reported total Scope 3 emissions of 606,351 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2025), Aurobindo Pharma's Scope 3 emissions increased by 68.33%, suggesting that the company faced challenges in reducing emissions across its value chain.a
In 2026, Aurobindo Pharma reported emissions for 6 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This partial disclosure allows for some insight into the company's indirect impacts.
In 2026, the largest contributors to Aurobindo Pharma's Scope 3 emissions were:a
In 2026, Aurobindo Pharma reported Scope 1 greenhouse gas (GHG) emissions of 912,276 tCO₂e and total revenues of USD 3,575 millions. This translates into an emissions intensity of 255.17 tCO₂e per millions USD.a
In 2026, Aurobindo Pharma reported a Scope 1 emissions intensity of 255.17 tCO₂e per millions USD. Compared to the peer group median of 25.65, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2026, Aurobindo Pharma ranked 24 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Aurobindo Pharma among the least efficient performers, with one of the highest emissions intensities in its sector.a
In 2026, Aurobindo Pharma reported a total carbon footprint of 2,051,913 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 29.41% increase compared to 2025, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Aurobindo Pharma's total carbon footprint was Scope 1 emissions, accounting for 44.46% of the company's total carbon footprint, followed by Scope 3 emissions at 29.55%.a